MedTrace Logo

COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study

NCT05301881 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2025-02-05

No results posted yet for this study

Summary

Patients with oligoprogression of metastatic breast cancer during palliative treatment that is amenable to local therapy will be included. The local ablative therapy (LAT) may consist of stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiation therapy, surgery or radiofrequency ablation (RFA).

Conditions

Interventions

PROCEDURE

Surgery

resection of the oligometastatic lesion(s)

RADIATION

Radiotherapy

radiation of the oligometastatic lesion(s)

OTHER

Radiofrequent ablation

radiofrequent ablation of the oligometastatic lesion(s)

Sponsors & Collaborators

  • Maarten van de Weijden Foundation

    collaborator UNKNOWN

  • The Netherlands Cancer Institute

    lead OTHER

Principal Investigators

  • G Sonke · The Netherlands Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-17
Primary Completion
2035-04-01
Completion
2040-04-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05301881 on ClinicalTrials.gov